NetworkNewsBreaks – Why Lexaria Bioscience Corp.
Post# of 420
(Total Views: 280)
Posted On: 07/20/2021 4:29:28 PM
NetworkNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’
Lexaria Bioscience Corp. (NASDAQ: LEXX) is the global innovator behind the patented DehydraTECH(TM) technology. DehydraTECH increases the effectiveness of lipophilic (fat-soluble) drugs and active ingredients and improves the way active pharmaceutical ingredients enter the bloodstream. It speeds up delivery, increases bioavailability, increases brain absorption, improves drug potency, reduces drug administration cost and masks unwanted taste. A recent article reads, “Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats. The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings.” Led by an experienced management team, Lexaria is focusing its ongoing research and development efforts on developing product candidates across several key billion-dollar segments: oral cannabinoids, antivirals, oral mucosal nicotine, human hormones, ibuprofen and Naproxen, and vitamin D3. The antivirals segment, for example, is “an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX) is the global innovator behind the patented DehydraTECH(TM) technology. DehydraTECH increases the effectiveness of lipophilic (fat-soluble) drugs and active ingredients and improves the way active pharmaceutical ingredients enter the bloodstream. It speeds up delivery, increases bioavailability, increases brain absorption, improves drug potency, reduces drug administration cost and masks unwanted taste. A recent article reads, “Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats. The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings.” Led by an experienced management team, Lexaria is focusing its ongoing research and development efforts on developing product candidates across several key billion-dollar segments: oral cannabinoids, antivirals, oral mucosal nicotine, human hormones, ibuprofen and Naproxen, and vitamin D3. The antivirals segment, for example, is “an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼